Satori pins Alzheimer's hopes on selectively modulating gamma secretase; gains $15M funding
This article was originally published in Scrip
Satori Pharmaceuticals, a US company founded in 2005, raised $15 million in an insider round to fund the development of selective modulators of gamma secretase that might slow or stop the progression of plaque build-up in Alzheimer's disease. Gamma secretase was the target of Eli Lilly's ill-fated Alzheimer drug semagacestat, an inhibitor of the enzyme, and of other now-withdrawn inhibitors. However, Satori believes that modulation of the enzyme rather than outright inhibition can avoid the toxic impact that caused Lilly to curtail semagacestat's development.